SwePub
Sök i LIBRIS databas

  Utökad sökning

hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Mikrobiologi inom det medicinska området)
 

Sökning: hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Mikrobiologi inom det medicinska området) > Lot-to-lot immunoge...

  • Ferguson, MurdoColchester Research Group, Canada,Colchester Res Grp, Truro, NS B2N 1L2, Canada. (författare)

Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • Elsevier,2024
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:bth-26212
  • https://urn.kb.se/resolve?urn=urn:nbn:se:bth-26212URI
  • https://doi.org/10.1016/j.jvacx.2024.100494DOI
  • https://lup.lub.lu.se/record/29ffab4a-56ce-48de-bb98-8912cd79fa75URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-532544URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background: Previous phase 3 studies showed that the AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine for older adults (RSVPreF3 OA) is well tolerated and efficacious in preventing RSV-associated lower respiratory tract disease in adults ≥ 60 years of age. This study evaluated lot-to-lot immunogenicity consistency, reactogenicity, and safety of three RSVPreF3 OA lots. Methods: This phase 3, multicenter, double-blind study randomized (1:1:1) participants ≥ 60 years of age to receive one of three RSVPreF3 OA lots. Serum RSVPreF3-binding immunoglobulin G (IgG) concentration was assessed at baseline and 30 days post-vaccination. Lot-to-lot consistency was demonstrated if the two-sided 95 % confidence intervals (CIs) of the RSVPreF3-binding IgG geometric mean concentration (GMC) ratios between each lot pair at 30 days post-vaccination were within 0.67 and 1.50. Solicited adverse events (AEs) within four days, unsolicited AEs within 30 days, and serious AEs (SAEs) and potential immune-mediated diseases within six months post-vaccination were recorded. Results: A total of 757 participants received RSVPreF3 OA, of whom 708 were included in the per-protocol set (234, 237, and 237 participants for each lot). Lot-to-lot consistency was demonstrated: GMC ratios were 1.06 (95 % CI: 0.94–1.21), 0.92 (0.81–1.04), and 0.87 (0.77–0.99) between the lot pairs (lot 1/2; 1/3; 2/3). For the three lots, the RSVPreF3-binding IgG concentration increased 11.84-, 11.29-, and 12.46-fold post-vaccination compared to baseline. The reporting rates of solicited and unsolicited AEs, SAEs, and potential immune-mediated diseases were balanced between lots. Twenty-one participants reported SAEs; one of these–a case of atrial fibrillation–was considered by the investigator as vaccine-related. SAEs with a fatal outcome were reported for four participants, none of which were considered by the investigator as vaccine-related. Conclusion: This study demonstrated lot-to-lot immunogenicity consistency of three RSVPreF3 OA vaccine lots and indicated that the vaccine had an acceptable safety profile. ClinicalTrials.gov: NCT05059301. © 2024 GSK

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Murray, AlexanderPharmQuest, 806 Green Valley Rd Ste 305, Greensboro, NC 27408 USA. (författare)
  • Pliamm, LewCanadian Phase Onward Inc, Polyclin Family & Specialty Med Facil, Polyclin Family Hlth Grp, 2 Champagne Dr, Toronto, ON M3J 0K2, Canada. (författare)
  • Rombo, LarsUppsala universitet,Uppsala University,Centrum för klinisk forskning i Sörmland (CKFD),Institutionen för medicinsk biokemi och mikrobiologi,Clinical Research Centre Sörmland(Swepub:uu)larra728 (författare)
  • Sanmartin Berglund, Johan,ProfessorBlekinge Institute of Technology,Lund University,Lunds universitet,Blekinge Tekniska Högskola,Institutionen för hälsa,Geriatrik,Forskargrupper vid Lunds universitet,Geriatric Medicine,Lund University Research Groups,Geriatrics,Blekinge Inst Technol, Dept Hlth, Valhallavagen 1, SE-37179 Karlskrona, Sweden.;Lund Univ, Dept Clin Sci, BMC I12, SE-22184 Lund, Sweden.(Swepub:lu)smi-jbe (författare)
  • David, Marie-PierreGSK, Ave Fleming 20, B-1300 Wavre, Belgium.,GlaxoSmithKline Pharmaceuticals SA (författare)
  • De Schrevel, NathalieGSK, Rue Inst 89, B-1330 Rixensart, Belgium.,GlaxoSmithKline Pharmaceuticals SA (författare)
  • Maschino, FranckGSK, Ave Fleming 20, B-1300 Wavre, Belgium.,GlaxoSmithKline Pharmaceuticals SA (författare)
  • Kotb, ShadyGSK, Ave Fleming 20, B-1300 Wavre, Belgium.,GlaxoSmithKline Pharmaceuticals SA (författare)
  • Olivier, AurélieGSK, Ave Fleming 20, B-1300 Wavre, Belgium.,GlaxoSmithKline Pharmaceuticals SA (författare)
  • Hulstrøm, VeronicaGSK, Ave Fleming 20, B-1300 Wavre, Belgium.,GlaxoSmithKline Pharmaceuticals SA (författare)
  • Colchester Research Group, CanadaColchester Res Grp, Truro, NS B2N 1L2, Canada. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Vaccine: X: Elsevier182590-1362

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy